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Background: The prevalence and type of plasmids, resistance genes and integrons carried by two collections of
multiresistant E. coli producing or not extended-spectrum β-lactamases have been compared. Rep-PCR was used to
determine the clonal relationship of the organisms. Plasmids were classified according to their incompatibility. Class
1 and Class 2 integrons and antibiotic resistance genes were analysed by PCR and sequencing.
Results: Both collections of organisms contained a large diversity of unrelated strains with some clones distributed
in both groups of isolates. Large plasmids were identified in the two groups of organisms. Plasmids with replicons
repK and repColE were more frequent among ESBL-producing isolates, while repFIA, repFII and repA/C replicons were
more frequent in isolates lacking ESBL. Conjugative plasmids with repK and repA/C replicons coded for CTX-M-14
and CMY-2 β-lactamases, respectively. No significant differences were observed in the distribution of class 1 and
class 2 integrons among multiresistant E. coli producing or not ESBL, and dfrA17-ant(3″)-Ie was the cassette
arrangement most commonly found.
Conclusions: In the concrete temporal and geographical context of this study, multiresistant E. coli producing ESBL
or other mechanisms of resistance were largely clonally diverse and present some differences in the types of
harboured plasmids. Still, some clones were found in both ESBL-producing and –lacking isolates.
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A rapid dissemination of Escherichia coli and others ente-
robacteria producing extended-spectrum beta-lactamases
(ESBLs) has been reported in many European countries,
including Spain, and is a matter of major concern [1,2].
The blaCTX-M genes are becoming the most prevalent
ESBLs encountered in Enterobacteriaceae [2]. The preva-
lent blaCTX-M-type genes in Europe have been identified
as blaCTX-M-1, blaCTX-M-3, blaCTX-M-9, blaCTX-M-14 and
blaCTX-M-15 [2]. Infections caused by enterobacteria pro-
ducing ESBL are associated with increased morbidity,
mortality, and health-care associated costs [3].* Correspondence: biolbelen@hotmail.com
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distribution, and reproduction in any mediumDuring recent years, extensive characterization of plasmid
families (usually by replicon typing [4,5] or, more recently,
by relaxase identification [6]) has provided additional infor-
mation on epidemiological aspects of transmissible anti-
microbial resistance [7]. Many of these studies have focused
on E. coli producing ESBL [8,9]. From these studies, some
plasmid families were demonstrated to be largely prevalent
in Enterobacteriaceae, emerging in association with specific
ESBL genes. For instance, the blaCTX-M-15 and blaCTX-M-3
genes have often been located on plasmids belonging to the
IncF group [10] and IncL/M family [11] respectively, in dif-
ferent countries [12-16]. It would be interesting to know if
in a specific geographical area, plasmid-mediated anti-
microbial resistance in multiresistant E. coli producing
ESBL is due to plasmids of the same incompatibility group
(s) as those present in other multirresistant isolates not pro-
ducing ESBL.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.biomedcentral.com/1471-2180/13/84The objective of this study was to determine whether
the clonal variability and content of plasmids, resistance
genes and integrons of clinical isolates of E. coli producing
ESBL (Ec-ESBL) were similar or not to those of E. coli iso-
lates lacking ESBL (Ec-MRnoB) isolated in the same geo-
graphical area and period.
Results
Phenotype of resistance and clonal relationship
MIC50 and MIC90 values of the different agents against
the two groups of multiresistant E. coli are presented in
Table 1. All Ec-ESBL were susceptible to cefotetan, imi-
penem, meropenem, amikacin and tigecycline. According
to the EUCAST [17], all Ec-ESBL isolates were resistant to
cefotaxime, 96% to cefepime, 96% to aztreonam and 23%
to ceftazidime (Table 1). Moreover, 39% of the isolates be-
longing to the Ec-ESBL collection were co-resistant to qui-
nolones, tetracycline and trimethoprim-sulfamethoxazole.
All Ec-MRnoB were susceptible to imipenem, mero-
penem, amikacin and tigecycline. Eight isolates in this
collection were resistant to at least one extended-
spectrum cephalosporin (ceftazidime) (Table 1). The
most frequent phenotype of resistance observed amongTable 1 MIC range, MIC50 (mg/L) and MIC90 (mg/L) values of 2
isolates, and percentages of resistant isolates to the indicate
Ec-ESBL (N=100)
Agent Range MIC50 MIC
Amoxicillin 64-≥256 ≥256 ≥25
Amoxicillin-Clavulanic acid 8-16 4 8
Piperacillin 32-≥64 ≥64 ≥64
Piperacillin-Tazobactam ≤0.5-≥256 4 16
Cefoxitina ≤2-32 ≤2 8
Cefotetana ≤1-8 ≤1 ≤1
Cefotaxime 32-≥128 ≥128 ≥12
Ceftazidime ≤0.5-≥128 2 16
Cefepime ≤1-≥32 ≥32 ≥32
Aztreonam 2-≥64 16 ≥64
Imipenem ≤0.5-1 ≤0.5 ≤0.
Meropenem ≤0.5 ≤0.5 ≤0.
Gentamicin ≤0.5-≥256 1 32
Tobramycin 0.5-256 1 8
Amikacin ≤0.5-8 2 4
Nalidixic acida 1-≥256 ≥256 ≥25
Ciprofloxacina ≤0.5-≥256 16 128
Tetracyclinea 0.5-≥256 256 256
Doxycyclinea ≤0.5-128 16 64
Tigecyclineb ≤0.5-1 ≤0.5 ≤0.
Trimethoprim-Sulfamethoxazole ≤0.5-≥32 ≥32/608 ≥32
a CLSI 2011 breakpoints. b FDA breakpoints.the selected Ec-MRnoB isolates included resistance
to β-lactams (amoxicillin), aminoglycosides [gentami-
cin alone or (more often) associated to tobramycin],
quinolones (nalidixic acid alone or associated to ciproflox-
acin), tetracyclines (tetracycline alone or associated to
doxycycline) and trimethoprim-sulfamethoxazole, occur-
ring in 50% of the studied isolates. All other possible com-
binations of co-resistances among the selected isolates
represented no more than 5% of the isolates.
Most Ec-ESBL were of phylogroup B1 (38%), followed by
groups A (32%), D (22%) and B2 (8%). In contrast, the
most frequent phylogenetic group of Ec-MRnoB was D
(46%), followed by groups A (25%), B2 (17%) and B1 (12%).
The 100 Ec-ESBL isolates were grouped in 66 Rep-
PCR patterns. In this group, only 2 Rep-PCR patterns
included 5 or more isolates: patterns XXXI (n=6, phylo-
genetic group A) and XXII (n=5; B1). The remaining
patterns contained 2 to 4 isolates (16 Rep-PCR patterns)
or single isolates (48 Rep-PCR patterns). Lower clonal
variability was noted among the Ec-MRnoB, which were
grouped into 40 Rep-PCR patterns. Three patterns in-
cluded 5 or more isolates: I-NB (n=18, phylogenetic
group D), II-NB (n=14; B2) and XXIII-NB (n=8; D).1 antimicrobial agents for Ec-ESBL and Ec-MRnoB
d agents (EUCAST breakpoints, except where indicated)
Ec-MRnoB (N=100)
90 %R Range MIC50 MIC90 %R
6 100 2-≥256 ≥256 ≥256 99
41 8-≥128 8 32 83
100 ≤16-≥64 ≥64 ≥64 84
16 ≤0.25-≥256 2 4 6
5 ≤2-≥32 4 8 8
0 ≤1-≥32 ≤1 ≤1 2
8 100 ≤0.5-128 ≤0.5 ≤0.5 5
23 ≤0.5-128 ≤0.5 ≤0.5 8
96 ≤1-4 ≤1 <1 1
96 ≤0.5-32 ≤0.5 ≤0.5 6
5 0 ≤0.5-2 ≤0.5 ≤0.5 0
5 0 ≤0.5 ≤0.5 ≤0.5 0
19 0.5-≥256 64 256 96
17 ≤0.25-256 8 32 89
0 1-8 2 4 0
6 89 1-≥256 ≥256 ≥256 98
74 ≤0.25-≥256 32 128 93
80 ≤0.25-256 256 256 84
76 ≤0.25-128 32 64 79
5 0 ≤0.25-0.5 ≤0.25 ≤0.25 0
/608 67 ≤0.5-≥32 ≥32/608 ≥32/608 98
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http://www.biomedcentral.com/1471-2180/13/84Fifteen patterns included 2 to 4 isolates, and the re-
maining 22 patterns corresponded to single isolates.
Comparison of Rep-PCR patterns corresponding to
isolates of the two E. coli collections showed the pres-
ence of Ec-ESBL (5 Rep-PCR patterns corresponding to
11 isolates) and Ec-MRnoB (4 Rep-PCR patterns corre-
sponding to 30 isolates) with the same pattern. PFGE
analysis confirmed this relationship, with isolates pre-
senting identical or similar [less than 5 bands of dif-
ference] PFGE patterns. In addition, clonally related
isolates (determined by Rep-PCR/PFGE) were included
in the same ST defined by MLST (Figure 1).
Twenty-four ST were identified among the isolates se-
lected for the conjugation assay (Table 2), of which
seven types included both Ec-ESBL and Ec-MRnoB,
while 11 and 6 types included either Ec-ESBL or
Ec-MRnoB, respectively. Three new ST (ST2292, ST2294
and ST2295) were first identified among our Ec-ESBL
isolates.
Plasmid profile
One or more plasmids were observed in organisms of the
two E. coli collections. For the 69 Ec-ESBL isolates the
most frequently detected replicons were repFIB (64/69,
92.8%), repFII (60/69, 87.0%), repColE (48/69, 69.6%), repK
(43/69, 62.3%) and repI1 (28/69, 41.0%). Other replicons

















































































































































































































Figure 1 Clonal relationship and plasmid profile of related isolates fro
AMX=amoxicillin, PIP= piperacillin; AMC=amoxicillin-clavulanic acid; CAZ=c
NAL=nalidixic acid, CIP=ciprofloxacin, TET= tetracycline, SXT= trimethoprimdetected in 2.9% to 17.4% of the isolates (Figure 2).
Among the 45 Ec-MRnoB, 4 major replicon types were
detected: repFIB (42/45, 93.3%), repFII (28/45, 62.2%),
repFIA (24/45, 53.3%) and repColE (23/45, 51.0%). Fur-
thermore, positive results were detected in some of these
isolates for other replicons, including repI1, repY, repP,
repB/O, repA/C, repR and repK (Figure 2).
Ec-ESBL and Ec-MRnoB isolates differed significantly
in the presence of 5 replicons: repK (p<0.001), repFII
(p=0.002) and repColE (p<0.001) were more frequent
among Ec-ESBL isolates, while repFIA (p<0.001) and
repA/C (p=0.030) were more frequent among Ec-MRnoB
isolates.
Nineteen ESBL-producing transconjugants were obtained
from the 20 Ec-ESBL isolates selected for the conjugations
assays (see Additional file 1). All transconjugants contained
one or more plasmids. The more frequently detected
replicons in the 19 transconjugants were: repK (14/19,
73.7%), repFII (11/19, 57.9%), repI1 (5/19, 26.3%) and repP
(2/19, 10.5%). With the three selective media used,
transconjugants were obtained from 13 out of the 20
Ec-MRnoB isolates selected for conjugation assays (see
Additional file 2). In all, 25 transconjugants were analysed,
including 12 selected with ampicillin, which contained
replicons repI1 (n=6), repFIB (n=5), repFII (n=4) and
repFIA (n=3), 10 selected with gentamicin [containing plas-











































ESBL, GEN, NAL, CIP, TET, DOX
ESBL, GEN, TOB, NAL, CIP, TET, DOX
ESBL, NAL, CIP, TET, DOX
ESBL, NAL, TET, DOX
ESBL, NAL, CIP, TET, DOX
AMX, GEN, TOB, NAL, TET, SXT
ESBL, FOX, NAL, CIP, SXT
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET
AMX, AMC, PIP, GEN, TOB, NAL,CIP, SXT, TET, DOX
AMX, AMC, PIP, GEN, TOB, NAL,CIP, SXT, TET, DOX
AMX, AMC, PIP, GEN, TOB, NAL,CIP, SXT, TET, DOX
AMX, FOX, GEN, TOB, NAL, CIP, SXT, TET
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, AMC, PIP, PTZ, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, AMC, PIP, GEN, TOB, NAL,CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
ESBL, NAL, CIP
ESBL, NAL, CIP, SXT, TET, DOX
ESBL, NAL, CIP, SXT, TET
ESBL, GEN, TOB, NAL, CIP, TET, DOX
AMX, AMC, PIP, PTZ, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, SXT, TET, DOX
GEN, TO, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL CIP, SXT, TET, DOX
GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, CIP, SXT
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, TOB, NAL, CIP, SXT, TET, DOX
ESBL, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, GEN, TOB, NAL, CIP, SXT, TET, DOX
AMX, PIP, GEN, NAL, CIP, SXT, TET, DOX
Replicon Typing
I1, FIB, FII, P
FIA, FIB, FII, K, ColE
FIA, FIB, FII, K, R
FIA, FIB, FII, K
FIA, FIB, FII, K
FIA, FIB, FII, ColE
FIB, FII, K
FIB, FII, B/O
FIA, FIB, FII, I1
FIA, FIB, FII, I1
FIA, FIB, FII







I1-I, FIA, FIB, FII
FIA, FIB, FII
FIA, FIB, FII
I1, FIA, FIB, FII
FIA, FII, K
I1-I, FIA, FII, K
FIA, FII, IncY
FIA, FIB, FII, K















m both collections. aESBL= extended-spectrum β-lactamases;
eftazidime, FOX=cefoxitin; GEN=gentamicin, TOB=tobramycin,
.-sulphamethoxazole.
Table 2 Clonal complexes (Cplx) and sequence types (ST) of 40 multiresistant E. coli producing ESBL (Ec-ESBL, n=20) or
not (EcMRnoB, n=20) selected for the conjugation assay
Isolate E. coli collection ST Cplx adk fumC gyrB icd mdh purA recA Rep-PCR Nª
HUMV-05/374 Ec-MRnoB ST1011 6 4 159 44 112 1 17 III-NB 3
HUMV-04/2539 Ec-ESBL ST117 20 45 41 43 5 32 2 V 2
HUMV-05/21 Ec-MRnoB ST117 20 45 41 43 5 32 2 XXIII-NB 8
HUMV-04/1119 Ec-MRnoB ST1210 187 11 4 8 8 8 2 IV-NB 3
HUMV-04/925 Ec-MRnoB ST1210 187 11 4 8 8 8 2 VI-NB 4
HUMV-04/3310 Ec-ESBL ST131 53 40 47 13 36 28 29 X 3
HUMV-05/46 Ec-MRnoB ST131 53 40 47 13 36 28 29 II-NB 14
HUMV-05/895 Ec-MRnoB ST131 53 40 47 13 36 28 29 II-NB 14
HUMV-04/2296 Ec-MRnoB ST131 53 40 47 13 36 28 29 XII-NB 1
HUMV-04/2830 Ec-ESBL ST155 ST155Cplx 6 4 14 16 24 8 XXII 5
HUMV-04/2103 Ec-ESBL ST156 ST156Cplx 6 29 32 16 11 8 44 XXXVII 3
HUMV-04/2283 Ec-ESBL ST167 ST10Cplx 10 11 4 8 8 13 2 XXXI 6
HUMV-05/868 Ec-MRnoB ST167 ST10Cplx 10 11 4 8 8 13 2 VI-NB 4
HUMV-05/881 Ec-MRnoB ST167 ST10Cplx 10 11 4 8 8 13 2 XXXV-NB 1
HUMV-04/2487 Ec-ESBL ST224 6 4 33 16 11 8 6 XXIV 2
HUMV-04/3181 Ec-MRnoB ST224 6 4 33 16 11 8 6 X-NB 3
HUMV-04/3218 Ec-MRnoB ST224 6 4 33 16 11 8 6 XVII-NB 1
HUMV-04/1412 Ec-ESBL ST2292 6 65 15 18 9 8 6 LIII 1
HUMV-04/1391 Ec-ESBL ST2296 8 7 1 8 6 8 7 XXII 5
HUMV-05/284 Ec-ESBL ST2295 8 7 14 8 8 8 6 XVII 3
HUMV-04/3168 Ec-MRnoB ST23 ST23Cplx 6 4 12 1 20 13 7 XXXIX-NB 2
HUMV-05/268 Ec-MRnoB ST354 ST354Cplx 85 88 78 29 59 58 62 I-NB 18
HUMV-05/310 Ec-MRnoB ST354 ST354Cplx 85 88 78 29 59 58 62 I-NB 18
HUMV-05/281 Ec-ESBL ST359 43 41 15 90 11 8 6 XIV 4
HUMV-05/508 Ec-ESBL ST359 43 41 15 90 11 8 6 XIV 4
HUMV-04/1087 Ec-ESBL ST362 62 100 17 31 5 5 4 XXIII 2
HUMV-04/3096 Ec-ESBL ST393 ST31Cplx 18 106 17 6 5 5 4 III 4
HUMV-05/631 Ec-MRnoB ST393 ST31Cplx 18 106 17 6 5 5 4 XV-NB 3
HUMV-04/2833 Ec-ESBL ST538 ST538Cplx 13 40 19 13 36 28 30 IV 3
HUMV-04/1630 Ec-ESBL ST57 ST350Cplx 6 31 5 28 1 1 2 XXXIX 2
HUMV-05/190 Ec-ESBL ST617 ST10Cplx 10 11 4 8 8 13 73 II 3
HUMV-04/3317 Ec-ESBL ST617 ST10Cplx 10 11 4 8 8 13 73 XXXI 6
HUMV-04/2942 Ec-ESBL ST641 ST86Cplx 9 6 33 131 24 8 7 XVI 2
HUMV-04/1012 Ec-ESBL ST648 92 4 87 96 70 58 2 LVIII 2
HUMV-05/630 Ec-MRnoB ST648 92 4 87 96 70 58 2 XXXI-NB 1
HUMV-04/1002 Ec-MRnoB ST69 ST69Cplx 21 35 27 6 5 5 4 IX-NB 4
HUMV-04/1725 Ec-ESBL ST88 ST23Cplx 6 4 12 1 20 12 7 XXXVI 2
HUMV-05/569 Ec-MRnoB ST88 ST23Cplx 6 4 12 1 20 12 7 XXIV-NB 4
HUMV-05/523 Ec-MRnoB ST88 ST23Cplx 6 4 12 1 20 12 7 XXX-NB 1
HUMV-04/979 Ec-MRnoB ST93 ST168Cplx 6 11 4 10 7 8 6 XXXVII-NB 1
aTotal number of isolates belonging to the indicated Rep-PCR pattern.

















A/C B/O ColE FIA FIB FII HI2 I1 K L/M N P R Y
Ec-ESBL  Ec-MRnoB
Figure 2 Distribution of replicons on plasmids identified in multiresistant E. coli isolates producing ESBL (Ec-ESBL, n=69) or lacking
these enzymes (Ec-MRnoB, n=45). *p value <0.05.
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http://www.biomedcentral.com/1471-2180/13/84(n=4)] and three selected with sulfamethoxazole, [with plas-
mids containing repFIB (n=2), repFIA (n=2) and repFII
(n=2) replicons].
Detection of resistance genes in wild-type strains and
transconjugants
In the 69 Ec-ESBL isolates, genes coding for the following
ESBL were detected: blaCTX-M-14 (51/69, 73.9%), blaSHV-12
(11/69, 15.9%), blaCTX-M-1 (6/69, 8.7%), blaSHV-2 (5/69,
7.2%), blaCTX-M-9 (2/69, 2.9%) and blaTEM-200 (1/69, 1.4%,
first identified in this study). In addition, TEM-1 was
detected in 33 (47.8%) isolates. No positive PCR results
were obtained in this collection for genes coding for
plasmid-mediated AmpC-β-lactamases. The ESBL genes
produced by the 19 obtained transconjugants were:
blaCTX-M-14 (16/19, 84.2%), blaCTX-M-9 (1/19, 5.3%),
blaSHV-12 (1/19, 5.3%) and blaTEM-200 (1/19, 5.3%).Plasmid Extraction RFLP
IncK-CTX-M-14
Figure 3 Restriction patterns to the IncK-CTX-M-14-plasmids belong tHybridization assays showed that the gene coding for
CTX-M-14 was mobilizable by IncK plasmids. Moreover,
the RFLP of plasmids from 13 IncK-CTX-M-14 showed
the same restriction pattern in 8 isolates (Figure 3) (unfor-
tunately, for the remaining 5 isolates the assay did not
allow the production of a restriction pattern).
Amoxicillin resistance in the 45 Ec-MRnoB isolates
was related to genes coding for TEM-1 (36/45, 80%),
SHV-11 (2/45, 4.4%), SHV-1 (1/45, 2.2%) or OXA-1
(1/45, 2.2%). The relationship between amoxicillin re-
sistance and TEM-1 production in these organisms
was confirmed by detecting the corresponding gene in
24 out the 25 (96%) obtained transconjugants. The Ec-
MRnoB resistant to both extended-spectrum cephalo-
sporins and cefoxitin contained the gene coding for
CMY-2, which was included in IncA/C plasmids, as









o transconjugants obtained from the ESBL collection.
Table 4 Distribution of gene cassette arrays found in
class 1 integrons among phylogenetic groups of E. coli
belongs to Ec-MRnoB collection
Phylogenetic groups (number of isolates)
Cassettes Total A (N=14) B1 (N=9) B2 (N=7) D (N=15)
ant(3″)-Ia 5 0 3 (33.3%) 1 (14.3%) 1 (6.7%)
dfrA1-ant(3″)-Ia 6 3 (21.4%) 1 (11.1%) 0 2 (13.3%)
blaOXA-1-ant(3″)-Ia 1 1 (7.1%) 0 0 0
dfrA12-ant(3″)-Ib 3 1 (7.1%) 0 1 (14.3%) 1 (6.7%)
dfrA16-ant(3″)-Ib 0 0 0 0 0
dfrA17-ant(3″)-Ie 16 4 (28.6%) 2 (22.2%) 4 (57.1%) 6 (40%)
ant(2″)-Ia 1 0 0 0 1 (6.7%)
ant(3″)-Ia-ant(2″)-Ia 2 2 (14.3%) 0 0 0
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http://www.biomedcentral.com/1471-2180/13/84None of the 69 Ec-ESBL or the 45 Ec-MRnoB
contained any of the studied plasmid-mediated quin-
olone resistance genes.
In the 69 Ec-ESBL isolates, class 1, class 2 or class 1
plus class 2 integrons were detected in 33.3%, 10.1% and
2.9% isolates, respectively (Table 3). Similarly, for the 45
Ec-MRnoB, positive results for class 1, class 2, and class
1 plus class 2 integrons were obtained for 75.6%, 4.4%,
and 6.7% of the isolates (Table 4). The gene cassette ar-
rays found in class 1 integrons for both E. coli collec-
tions are shown in Tables 3 and 4.
Discussion
This study presents comparative information about the
microbiological characteristics of two groups of multi-
resistant clinical isolates of E. coli (producing or not pro-
ducing ESBL, respectively), recovered in the same
geographical and temporal context.
Analysis of Rep-PCR shows a wide clonal distribution
among Ec-ESBL isolates and to a lesser extent among
Ec-MRnoB isolates. This variability indicates that, in our
area, multiresistance in E. coli is not always caused by
the expansion of only one or a few clones, but it is often
caused by the presence of multiple independent strains.
The diversity of E. coli strains producing extended-
spectrum beta-lactamase has been previously reported in
a nationwide study in Spain [18]. In addition, MLST also
showed evidences of small clusters of strains belonging
to clonal complexes 354, 10 and 23 or to the sequence
types 131, 224, 648 and 117. All these clonal groups have
been previously described [19-21] as involved in the
spread of certain genes coding for ESBLs and other re-
sistance mechanisms.
Isolates belonging to the ST354Cplx have been related
worldwide to the spread of ESBLs of the CTX-M family,
associated with the presence of plasmids of different in-
compatibility groups [19,22]. In Spain, Mora et al. [19]
have reported an increased prevalence of strains ofTable 3 Distribution of gene cassette arrays found in
class 1 integrons among phylogenetic groups of E. coli
belongs to Ec-ESBL collection
Phylogenetic groups (number of isolates)
Cassettes Total A (N=23) B1 (N=26) B2 (N=5) D (N=15)
ant(3″)-Ia 3 2 (8.7%) 0 0 1 (6.7%)
dfrA1-ant(3″)-Ia 7 4 (17.4%) 2 (7.7%) 0 1 (6.7%)
blaOXA-1-ant(3″)-Ia 1 1 (4.3%) 0 0 0
dfrA12-ant(3″)-Ib 0 0 0 0 0
dfrA16-ant(3″)-Ib 4 2 (8.7%) 1 (3.8%) 0 1 (6.7%)
dfrA17-ant(3″)-Ie 8 3 (13%) 1 (3.8%) 1 (20%) 3 (20%)
ant(2″)-Ia 0 0 0 0 0
ant(3″)-Ia-ant(2″)-Ia 0 0 0 0 0ST354 producing CTX-M-14. However, in our study, the
ST354 isolates do not produce an ESBL.
The ESBL-producing isolates of the ST10Cplx contained
either IncK or IncI1 plasmids, as also described by other
authors [23]. IncI1 plasmids have previously been identi-
fied in strains of human origin (both in patients and car-
riers) and in the commensal bacterial flora of diseased
animals [24]. ST10Cplx isolates were also identified
among non-ESBL detected in our study, but they did not
contain IncI1 plasmids.
It has been previously demonstrated that E. coli O25:
H4-ST131 is associated to the pandemic dissemination of
the CTX-M-15 enzyme but this clone was also prevalent
in healthy subjects from different European countries [1].
In a recent study on 100 consecutive extraintestinal E. coli
isolates cultured in 2009, the ST131 clone represented 9%
of all E. coli and about 25% of all multiresistant isolates in
our centre [25]. In the current study, ST131 strains were
also identified in both Ec-ESBL and Ec-MRnoB isolates.
CTX-M-14 was the most frequent ESBL identified in
our Ec-ESBL isolates. In most cases the gene coding for
this enzyme was in IncK plasmids and less frequently in
an IncI1 plasmid, in agreement with a previous Spanish
report [23]. Moreover, the IncK plasmids identified in this
study showed identical restriction patterns (Figure 3),
which suggest that the transmission of CTX-M-14 in our
sanitary area is due to a specific plasmid belonging to this
incompatibility group. Other reports have also shown the
importance of CTX-M-14 in other countries, that was dis-
seminated associated to IncFII plasmids [26,27].
The detection of both IncK and IncI1 plasmids in the
Ec-MRnoB collection indicates that these mobile ele-
ments are not only important for ESBL dispersion, but
may also be relevant for the transmission of other resist-
ance mechanism, as suggested in previous reports [7].
On the other hand, resistance to expanded-spectrum
cephalosporins associated to the production of the


































































































































































































Figure 4 Clonal relationship between isolates selected for conjugation assays in both E. coli collections. A) Ec-ESBL, B) Ec-MrnoB.
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http://www.biomedcentral.com/1471-2180/13/84a different group of plasmids, namely those of the IncA/
C group. IncA/C plasmids coding for CMY-2 have also
been previously described in E. coli and Salmonella
enterica isolates [7]. Moreover, 4 isolates were resistant
to ceftazidime but they did not present plasmid-
mediated AmpC β-lactamases, we presume that hy-
perproduction of AmpC was due to mutation in the
promotor or the attenuator of the corresponding gene,
as observed previously by others authors [28].
Plasmid typing showed that the dichotomous distribu-
tion of CTX-M-14 and CMY-2 among the two E. coli
groups corresponded to an unequal distribution of two
plasmid types associated to these enzymes: the A/C plas-
mids carrying CMY-2 were unique to the EcMRnoB
group, while the IncK plasmids carrying CTX-M-14
were related to the Ec-ESBL group.
Interestingly, other plasmid species were common and
highly represented in the two groups of isolates: IncF,
ColE and IncI1. The high prevalence of IncF plasmids in
both Ec-ESBL and Ec-MRnoB clearly indicates that this
plasmid species is very well adapted in resistant E. coli
strains independently of their resistance phenotype. A
recent report has demonstrated that F replicons (FIA,
FIB, FIC and FII) were the most frequently detected rep-
licon types in E. coli strains producing or not producing
ESBL [29]. Replicons of the IncF type were detected in
50% of E. coli from faeces of healthy, antibiotic-free
humans and faecal flora from healthy birds in the USA,
confirming that this plasmid type can be highly repre-
sented in E. coli populations also including susceptible
strains [24]. Similarly, IncI1 plasmids have also been
detected in E. coli from faecal flora of healthy humans
and animals [24]. Finally, ColE plasmids are small, high
copy number, not self-conjugative, producing bacterio-
cins, whose prevalence is not well estimated in recent
collections of Enterobacteriaceae.
Several studies [30,31] have indicated that extra-
intestinal E. coli isolates are more commonly of phylo-
genetic groups B2 and D than of groups A and B1. In
our series, groups D and B2 were more frequent in the
Ec-MRnoB collection than in the Ec-ESBL. The de-
creased level of resistance among isolates of group B2
reported in some studies [32] was not observed in our
case, as per definition all isolates were multiresistant. Al-
though multiple studies indicate that use of fluoro-
quinolones is an independent factor for infections by
multiresistant E. coli, plasmid-mediated quinolone resist-
ance genes were not found among the isolates we have
studied. The most likely explanation for quinolone re-
sistance in our isolates is the presence of chromosomal
mutations in their gyrase and topoisomerase IV genes.
In addition to the indicated resistance genes, we have
found that the clinical isolates of multiresistant E. coli in
our health area carry different classes of integrons. Ec-MRnoB showed a higher presence of these elements in
comparison with the isolates belonging to the Ec-ESBL
collection but, in both cases, the class 1 integrons
containing dfrA17-ant(3′)Ie or dfrA1-ant(3″)-Ia genes
were the most frequent ones. The implication of these
elements in the spread of resistance in Spain [33] has
been previously documented.
Conclusion
In conclusion, this study has shown that, in our area,
multiresistant E. coli producing either ESBL or other
mechanisms of resistance are clonally diverse, although
small clusters of related strains are also found. While
both Ec-ESBL and EcMRnoB frequently contained IncFI
plasmids, plasmids usually related to the most frequently
detected ESBL (CTX-M-14), are uncommonly found in
strains lacking this enzyme.
Methods
Bacterial isolates, susceptibility testing and clonal
relationship
Two hundred multiresistant E. coli (one per patient) pro-
ducing (n=100) or not producing ESBL (n=100), consecu-
tively obtained between January 2004 and February 2005 at
the Clinical Microbiology Service of the University
Hospital Marqués de Valdecilla (Santander, Spain) were ini-
tially considered for this study. The organisms were
obtained from urine (n=158) or from other samples (n=42,
including 17 wound exudates, 8 samples from blood, 6
sputum, 6 naso-pharyngeal lavage, 2 catheter, 2 ascitic li-
quid and 1 bronchoalveolar aspirate). One hundred and
sixteen isolates were from samples of patients admitted to
the hospital and 84 from outpatients (database from
Hospital Universitario Marqués de Valdecilla). No relevant
differences were observed in the distribution of these pa-
rameters when comparing Ec-ESBL and Ec-MRnoB.
Identification and preliminary susceptibility testing (in-
cluding ESBL production) of the isolates had been rou-
tinely performed with the WalkAway system (Dade
Behring, Inc., West Sacramento, Ca., USA) using gram-
negative MIC combo 1S panels. Confirmation of ESBL
production and determination of MICs of imipenem,
meropenem, aztreonam, piperacillin, cefoxitin, cefotetan,
cefotaxime, cefotaxime-clavulanic acid, ceftazidime,
ceftazidime-clavulanic acid and cefepime were performed
using Dried MicroScan ESβL plus (Dade Behring, Inc.,
West Sacramento, Calif.) panels according to the manufac-
turer’s recommendations. In addition, susceptibility testing
results of the following agents were confirmed by standard-
ized microdilution, according to the CLSI standard [18]:
amoxicillin (Sigma-Aldrich, Madrid, Spain), amoxicillin-
clavulanic acid (GlaxoSmithKline, United Kingdom) (2:1),
cefepime-clavulanic acid, piperacillin (Sigma-Aldrich)-
tazobactam (Wyeth Pharmaceuticals, Madrid, Spain),
Table 5 PCR conditions used for detection of antimicrobial resistance genes



















































tet (A) 5′-gctacatcctgcttgcct-3′ 210
5′-catagatcgccgtgaaga-3′
tet (B) 5′-ttggttaggggcaagttttg-3′ 600
5′-gtaatgggccaataacaccg-3′
Ruiz del Castillo et al. BMC Microbiology 2013, 13:84 Page 9 of 12
http://www.biomedcentral.com/1471-2180/13/84

















Ruiz del Castillo et al. BMC Microbiology 2013, 13:84 Page 10 of 12
http://www.biomedcentral.com/1471-2180/13/84amikacin (Sigma-Aldrich), gentamicin (Sigma-Aldrich),
tobramycin (Sigma-Aldrich), nalidixic acid (Sigma-Aldrich),
ciprofloxacin (Fluka, Madrid, Spain), tetracycline (Sigma-
Aldrich), doxycycline (Sigma-Aldrich), and trimethoprim
(Sigma-Aldrich)-sulfamethoxazole (Sigma-Aldrich) (19:1).
Fixed concentrations of 4 mg/L of tazobactam or clavulanic
acid were used in combination with piperacillin and
cefepime, respectively. The results were interpreted
according to the EUCAST breakpoints [17]. Isolates lack-
ing ESBL were selected for this study if resistant to at least
three of the following agents: amoxicillin, amoxicillin-
clavulanic acid, nalidixic acid, gentamicin or tobramycin
and trimethoprim-sulfamethoxazole. E. coli ATCC 25922
and K. pneumoniae ATCC 700603 were used as control
strains in susceptibility testing assays. Phylogenetic group-
ing of the 200 isolates was determined by multiplex PCR,
as described by Clermont et al. [19].
Clonal relationship was determined by Rep-PCR as pre-
viously described [20]. Amplicons were run in a 1.5% agar-
ose gel for 100 min, stained with ethidium bromide (Sigma
Chemical CO. St. Louis, USA) and photographed. Two iso-
lates were considered to be clonally unrelated when at least
two different bands were observed. Clonal relationship
among isolates was also determined by XbaI-PFGE [21]
when ESBL-producing isolates showed the same Rep-PCR
pattern than isolates lacking ESBL, these isolates were also
analysed by MLST, and this assay was also performed for
40 isolates selected for the conjugation assay representing
the most frequent Rep-PCR patterns of each E. coli collec-
tion (see below). Detection by PCR and sequencing of 7
housekeeping genes (gyrB, adk, purA, recA, icd, mdh and
fumC) were performed according to the E. coliMLST data-
base (http://mlst.ucc.ie/mlst/dbs/Ecoli).
Plasmid profile and hybridization experiments
After observing that some isolates with the same Rep-
PCR pattern presented different clinical categories of at
least two antimicrobial agents of different classes, 69
Ec-ESBL isolates and 45 Ec-MRnoB isolates were se-
lected for plasmid analysis and detection of plasmid-
mediated genes coding for resistance to β-lactams and
quinolones, according to the following criteria: a) allisolates from each Rep-PCR pattern with single isolates,
b) one isolate of each antimicrobial susceptibility pat-
tern from Rep-PCR patterns containing >=2 isolates.
Plasmid DNA was extracted by the Kado-Liu method
[22] and separated on 0.9% horizontal agarose gels elec-
trophoresis. Plasmids R27 (169 kb, Genbank access
AF250878), R1 (94 kb, Genbank access NC_003277),
RP4 (55 kb, [23]), and ColE1 (6 kb, Genbank access
J01566) were used as size standards.
Plasmids were also characterized by PCR-based repli-
con typing (PBRT), as described elsewhere, using the re-
spective PBRT controls [4,5]. The obtained amplicons
were sequenced to confirm their identity.
Plasmids were transferred onto nylon membranes by
southern blotting (Roche, Mannheim, Germany). Ampli-
cons from blaCTX-M-14 and blaCMY-2 were obtained by
PCR using DNA from E. coli CCG02 and E. coli B-12 [24],
respectively. Similarly, plasmids R387 and pIP40a [5] were
used to obtain PCR amplicons from repK and repA/C, re-
spectively. DNA probes prepared with DIG-High Prime
(Roche, Penzberg, Germany) were used to investigate the
presence of blaCTX-M-14 and repK genes in the same plas-
mid of Ec-ESBL isolates and of blaCMY-2 and repA/C genes
in the same plasmid of Ec-MRnoB isolates.
In 13 transconjugants of the belonging to ESBL collec-
tion the relationship among repK-CTX-M-14-plasmids
was determined by comparison of their DNA patterns
generated after digestion with the EcoRI and PstI en-
zymes and electrophoresis in 1.5% agarose, as described
elsewhere [25].
Conjugation assays
Conjugation assays were performed with 20 Ec-ESBL and
20 Ec-MRnoB, which are representative of the most com-
mon Rep-PCR/antibiotic resistance patterns (Figure 4).
E. coli J53 resistant to sodium azide was used as a re-
cipient strain. Transconjugants from the Ec-ESBL iso-
lates were selected with sodium azide (100 mg/L) plus
cefotaxime (2 mg/L), while for the Ec-MRnoB, trans-
conjugants were selected on three different media: so-
dium azide (100 mg/L) plus ampicillin (100 mg/L),
gentamicin (8 mg/L) or sulfamethoxazole (1000 mg/L).
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Five multiplex PCRs (Table 5) were performed using pre-
viously published conditions to detect genes that are usu-
ally included in conjugative plasmids: blaTEM, blaSHV,
blaOXA-1 and blaPSE-1 [26], plasmid-mediated AmpC-
type enzymes [27], blaCTX-M β-lactamases [26], plasmid-
mediated quinolone-resistance genes, including qnrA, qnrB,
qnrS, aac(6′)-Ib-cr and qepA [28] and tetracyclines-
resistance genes tet(A), tet(B) and tet(G) [26]. The iden-
tity of the complete genes detected by the multiplex
PCR was confirmed by specific PCR (using appropriate
primers) and sequencing of the two DNA strands. Fi-
nally, class 1 and class 2 integrons were detected by
PCR (Table 5) and the variable regions of class 1
integrons were sequenced using specific primers for the
3′CS and 5′CS ends as described elsewhere [29].
Statistical methods
The proportions of Ec-ESBL and of Ec-MRnoB isolates
containing different replicon elements were compared
by the chi-square test. Differences were considered sig-
nificant for p<0.05. The test was performed using the
SPSS 11.0 program.
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